Molecular Diagnostics Point of Care Market Expected to Reach USD 6.42 Billion by 2031 Growing at a CAGR of 10.38 Percent

"Molecular Diagnostics Point of Care Market" in terms of revenue was estimated to be worth $2.95 billion in 2023 and is poised to reach $6.42 billion by 2031, growing at a CAGR of 10.38% from 2024 to 2031 according to a new report by InsightAce Analytic.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1423

Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Molecular Diagnostics Point of Care market are:
• Rising Prevalence of Infectious Diseases
• Investments in Healthcare Facilities
• Integration with Digital Health Solutions

The following are the primary obstacles to the Molecular Diagnostics Point of Care market's expansion:
• Cost Constraints
• Limited Imbursement Policies
• Infrastructure and Connectivity Issues

Future expansion opportunities for the global Molecular Diagnostics Point of Care market include:
• Market Penetration in Emerging Markets
• Regulatory Compliance
• Point-of-Care Testing in Clinical Trials

Market Analysis:
The increasing prevalence of infectious diseases and chronic illnesses, such as cancer, is expected to serve as a major catalyst for market growth. This rise in disease burden has heightened the demand for advanced diagnostic solutions, thereby driving innovation in both technology and pharmacogenomics. Additionally, the development of personalized medicine and continued progress in diagnostic technologies present significant opportunities for market expansion. However, the high cost associated with implementation and the complexity of regulatory compliance may pose challenges that could limit the pace of growth.

List of Prominent Players in the Molecular Diagnostics Point of Care Market:
• Abbott Laboratories
• Bayer Healthcare
• Roche Diagnostics
• OraSure Technologies Inc.
• Nipro Diagnostics
• Bio-Rad Laboratories
• Danaher Corporation
• BioMerieux, Dako
• Abaxis Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Recent Developments:
• In February 2022, Sense Biodetection entered into a strategic agreement with Una Health (Una) for the United Kingdom distribution of the Veros Covid-19 test.
• In December 2021, FIND invested USD 21 million in Biomeme, Bioneer, Qlife, and SD Biosensor to accelerate the development, manufacturing, and launch of affordable point-of-care molecular diagnostic platforms that can detect multiple pathogens that cause diseases including COVID-19.
• In Oct 2018, QIAGEN negotiated with STAT-Dx to enhance its portfolio in testing solutions for next-gen PCR systems.
Market Dynamics

Market Drivers:
The global increase in infectious diseases-including COVID-19, influenza, HIV/AIDS, tuberculosis, and sexually transmitted infections-has substantially heightened the need for rapid, accurate diagnostic solutions at the point of care. Molecular point-of-care (POC) diagnostics address this need by delivering timely test results, enabling prompt clinical decision-making and improving the management of disease outbreaks. Additionally, the rising incidence of both infectious diseases and cancer in both developed and emerging markets is expected to drive further growth in the molecular POC diagnostics sector. The growing focus on preventive healthcare and early disease detection is also anticipated to support increased demand for these technologies throughout the forecast period.

Challenges:
Despite favorable market prospects, limited reimbursement support from public and private payers remains a significant barrier to the widespread adoption of molecular POC diagnostics. Current reimbursement models often fail to fully reflect the clinical benefits and cost-effectiveness of these technologies, potentially limiting their uptake by healthcare providers. Navigating reimbursement pathways continues to be a key challenge for diagnostic companies. For example, in 2018, Medicare revised its payment policies for certain in vitro diagnostic (IVD) tests, including molecular POC applications. Additionally, the American Society of Clinical Oncology has reported that Medicare does not cover genetic testing for individuals without a personal history of cancer. These reimbursement limitations may restrict broader clinical integration of molecular POC diagnostic solutions.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1423

North America Is Expected To Grow With the Highest CAGR during the Forecast Period
The molecular diagnostics point-of-care (POC) market in North America is projected to capture a substantial share of global revenue and demonstrate a strong compound annual growth rate (CAGR) over the forecast period. This anticipated growth is largely driven by the increasing prevalence of infectious diseases, a rise in the number of CLIA-waived product approvals, and the implementation of supportive regulatory frameworks. Furthermore, strategic initiatives by key market participants to enhance their competitive positioning are expected to further support regional market expansion.

The region also benefits from a growing volume of clinical research focused on improving the accuracy and applicability of molecular diagnostic technologies. Sustained demand for rapid and reliable diagnostic solutions, in conjunction with continuous technological advancements, evolving healthcare infrastructure, and favorable policy developments, is expected to reinforce North America's position as a leading market for molecular POC diagnostics.

Segmentation of Molecular Diagnostics Point of Care Market-
By Test Location-
• Over-the-counter (OTC)
• Point of Care (POC)
By Technology-
• PCR Based
• Genetic Sequencing Based
• Hybridization-Based
• Microarray-Based
• Nucleic Acid Amplification Testing (NAAT)
By Applications-
• Infectious Disease Testing
• Oncology
• Hematology
• Prenatal Testing
• Endocrinology
• Others
By End Users-
• Decentralized Labs
• Hospitals & Clinics
• Home Care Settings
• Assisted Living Healthcare Facilities
• Emergency Medical Services (EMS)
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-molecular-diagnostics-point-of-care-market/1423

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.